Inovio Pharmaceuticals Inc vs Uber Technologies Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $0.75 (market cap $78.55M), while Uber Technologies Inc trades at $76.4 (market cap $160.42B). The key difference: Uber Technologies Inc is far larger — about 2042.3× Inovio Pharmaceuticals Inc's market cap, and Uber Technologies Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | UBER | |
|---|---|---|
Market Cap | $78.55M | $160.42B |
Sector | Health | Industrials |
52-Week High | $2.87 | $100.10 |
52-Week Low | $0.66 | $65.94 |
Enterprise Value | $49.56M | $169.76B |
Signals from Pluang's Aura AI — not financial advice
INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.
Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.
Uber (UBER) trades at $78.03, up 4.01% today, with strong bullish technical signals and robust fundamentals including 2025 revenue of $52.02B and net income of $10.05B. Recent news highlights expansion in autonomous vehicle partnerships, such as the robotaxi pilot in Madrid with WeRide, while the company streamlines operations with HR layoffs and implements AI spending caps to manage costs.
The outlook remains positive with a consensus price target of $102.88, representing significant upside, driven by earnings beats and strategic initiatives in autonomous mobility. Key risks include competitive pressures in ride-hailing, regulatory scrutiny, and execution challenges in new technology deployments that could impact growth and margins.
Trailing returns across standard periods
Latest headlines on both assets
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →